T1	p 476 506	subjects > or =50 years of age
T2	p 509 548	Subjects with a negative history for HZ
T3	p 613 685	Enrollment was stratified 1:2 by age ( 50 to 59 years and > or =60 years
T4	i 133 141	Zostavax
T5	i 156 164	Zostavax
T6	i 391 399	Zostavax
T7	i 455 463	Zostavax
T8	i 1905 1913	Zostavax
T9	o 322 328	safety
T10	o 337 351	immunogenicity
T11	o 690 696	Safety
T12	o 741 790	Varicella-zoster virus ( VZV ) antibody responses
T13	o 902 941	VZV antibody geometric mean titer ( GMT
T14	o 959 997	VZV antibody geometric mean rise ( GMR
T15	o 1025 1089	incidence of vaccine-related serious adverse experiences ( AEs )
T16	o 1186 1190	GMTs
T17	o 1259 1262	GMT
T18	o 1376 1380	GMRs
T19	o 1424 1451	vaccine-related serious AEs
T20	o 1492 1498	safety
T21	o 1572 1590	injection-site AEs
T22	o 1747 1759	systemic AEs
T23	o 1806 1825	vaccine-related AEs
T24	o 1932 1938	safety
T25	o 1957 1968	immunogenic